Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
Phase 2 Unknown
50 enrolled
Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma
Phase 2 Unknown
200 enrolled
Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas
Phase 2 Unknown
80 enrolled
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer
Phase 3 Unknown
4,400 enrolled
Tamoxifen in Treating Women With Breast Cancer
Phase 3 Unknown
20,000 enrolled
Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
Phase 3 Unknown
Combination Chemotherapy in Treating Women With Breast Cancer
Phase 3 Unknown
350 enrolled
Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer
Phase 3 Unknown
300 enrolled
Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast
Phase NA Unknown
100 enrolled
CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen
Phase 2 Unknown
200 enrolled
Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer
Phase 3 Unknown
Comparison of Four Different Treatment Regimens in Treating Women With Stage I Breast Cancer
Phase 3 Unknown
Radiation Therapy and Tamoxifen in Treating Children With Newly Diagnosed Brain Stem Glioma
Phase 2 Unknown
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
Phase 3 Unknown
2,500 enrolled
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
Phase 2 Unknown
94 enrolled
Combination Chemotherapy in Treating Women With Resected Breast Cancer
Phase 2 Unknown
Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole
Phase 2 Unknown
2,000 enrolled